The Rescheduling Hearing Is Over. Nobody Will Tell You When the Answer Comes.

The DEA's hearing on moving marijuana to Schedule III wrapped up in Arlington this week, on schedule and with a strange scoreboard. The government, an agency that spent five decades defending prohibition, put on the strongest case in the room for cannabis as medicine. The seven parties invited to argue against the rule spent two weeks trying to poke holes in that case, and one of their marquee scientific witnesses conceded under cross-examination that cannabis meets the statutory criteria for Schedule III. A scoreboard like that would end most proceedings. This one moves to a waiting room with no clock. The presiding judge has no deadline to issue his recommendation, the DEA Administrator has no deadline to act on it, and the appeals court fight is already warming up.

Here's our read: the hearing was never really about persuading the judge. Both sides spent twelve days building a record for the D.C. Circuit, where this ends up no matter what anyone recommends. The testimony was discovery for a lawsuit that hasn't been filed yet.

What did the July hearing actually decide?

Nothing binding. The hearing built an evidentiary record on whether all botanical marijuana, adult-use included, belongs in Schedule III. Chief Administrative Law Judge Derek Julius now waits for post-hearing briefs, then issues a non-binding recommendation on his own timeline. The DEA Administrator makes the final call, also without a deadline, and that decision heads straight to the courts.

The mechanics: proceedings ran from June 29 through July 15 at DEA headquarters, with a recess over the July 4 weekend. No livestream, no broadcast, a public gallery of about 25 seats, and a promise that the corrected transcript gets published on DEA.gov after the fact. For the most consequential drug hearing in fifty years, the American public watched it through two reporters and some secondhand accounts.

The participant list was the controversy before a word of testimony was spoken. All seven designated parties oppose rescheduling: Smart Approaches to Marijuana, the National Drug & Alcohol Screening Association, DUID Victim Voices, physician Kenneth Finn, the Tennessee Bureau of Investigation, pharmacist Phillip Drum, and the states of Nebraska, Idaho, Indiana, and Louisiana. NORML asked to participate and was refused, twice. Not one supporter of the rule got a seat, which left the DEA itself as the lone voice defending its own proposal.

Why was the DEA arguing for cannabis?

Because the proposed rule was signed under the prior administration and the DEA, as its proponent, bears the burden of proving cannabis has a currently accepted medical use. Its two witnesses, an FDA scientist and a pain physician, argued exactly that, standing on the HHS finding that covers pain, chemotherapy nausea, and appetite loss.

The FDA's Dominic Chiapperino, who directed the review that produced the Schedule III recommendation, took the stand on day one and absorbed cross-examination from the opposition for two days. Dr. Corey Burchman, a New Hampshire pain specialist, followed with testimony on cannabis as an opioid substitute, telling the court that withdrawal from opioids is "like a dumpster fire" compared to coming off cannabis.

The opposition's two weeks produced two moments worth remembering. Harvard's Bertha Madras, testifying for Smart Approaches to Marijuana, attacked the clinical evidence on purity and dosing grounds, then acknowledged under DEA cross-examination that cannabis meets the statutory requirements for Schedule III. Her side's other move was subpoenaing the DEA's own in-house pharmacologist to testify about the harms of marijuana, over the DEA's objection. The prohibitionists calling a DEA scientist against the DEA, while the DEA resisted, is a detail you could not pitch to a screenwriter.

The states closed things out on July 14 with Yale's Deepak Cyril D'Souza on abuse liability and a Humboldt County sheriff on legalization-era crime in California, testimony aimed less at the judge than at the appellate record.

What happens between now and a decision?

Parties file proposed findings and post-hearing briefs. Julius issues a recommended decision, parties get 20 days to file exceptions, and the full record goes to the DEA Administrator for a final rule. Neither Julius nor the Administrator faces a deadline, and whatever comes out gets challenged in the D.C. Circuit.

The precedent is not encouraging on speed. The last full cannabis scheduling hearing of this type ended with ALJ Francis Young recommending rescheduling in 1988, the DEA Administrator rejecting his recommendation outright, and the D.C. Circuit blessing that rejection in 1994. Start to finish, close to a decade.

Two forces push against a repeat. Trump's December executive order demands the rulemaking be completed expeditiously, and the administration already showed in April that it will act by order when it wants to, moving medical cannabis to Schedule III in a single stroke. That April order is itself under attack at the D.C. Circuit, where challenges from SAM and the attorneys general of Nebraska and Indiana have been consolidated. The appellate machinery is running before the administrative one has finished.

So the honest timeline is: months at minimum, years if history rhymes, and no date anyone can circle.

Does any of this change what's on a dispensary shelf?

No. Medical cannabis and FDA-approved cannabis products moved to Schedule III in April and stay there regardless of this hearing. Dispensary edibles sell under state law either way. And the November 12 hemp ban runs on its own statute and its own clock, untouched by anything said in Arlington.

If the full rescheduling eventually lands, the practical wins go to adult-use operators (280E tax relief, easier research, banking that behaves like banking) and, in a quieter way, to displaced hemp products. Naturally derived hemp products that exceed the 0.4mg container cap after November 12 fall back into the marijuana definition, and a marijuana that sits in Schedule III carries lighter federal exposure than one in Schedule I. That changes the felony math for operators without changing what a consumer can legally buy at a smoke shop, which is still nothing with meaningful THC in it.

For anyone buying edibles for a condition, the item that mattered already happened in April. Medical cannabis under a state license is a Schedule III substance today. That reclassification, not this hearing, is what moves research money and physician comfort over the next few years. The Arlington proceeding was about the rest of the plant, and the rest of the plant now waits on a judge with no deadline, an administrator with no deadline, and a court that hasn't been asked yet.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Cannabis laws vary by jurisdiction and are changing rapidly.